MedTrace Logo

Muscle Fatigue and Carbonic Anhydrase Inhibitors

NCT02758470 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2018-09-25

No results posted yet for this study

Summary

The objective of this research is to assess the effects of acetazolamide and methazolamide on respiratory and limb muscle fatigue development. A fatiguing protocol will be conducted for the respiratory and plantar flexor muscles and the difference in pressure/torque produced by supramaximal nerve stimulation used to assess muscle fatigue between conditions.

Conditions

Interventions

DRUG

Acetazolamide

250 mg, taken orally three times per day

DRUG

Methazolamide

100mg, taken orally two times per day. A placebo pill will be taken between each dose of methazolamide to match the timing of doses and the number of pills between study arms.

OTHER

Placebo

A placebo will be taken three times per day

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Glen E Foster, Ph.D. · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02758470 on ClinicalTrials.gov